Libby's H*O*P*E*

*Helping*Ovarian Cancer Survivors*Persevere Through*Education

Menu

Skip to content
  • Home
  • About
  • Mission
  • Warning Signs & Symptoms
  • Ovarian Cancer Overview
  • Prevention, Early Detection/Screening & Causes
  • Genetics
  • Types of Ovarian Cancer
  • Diagnosis & Staging
  • Treatment Overview
  • Surgery
  • Chemotherapy
  • Radiology & Radiation Therapy
  • Hormonal (Anti-Estrogen) Therapy
  • Biological (Immunotherapy & Vaccine) Therapy
  • Gene Therapy
  • Alternative & Complementary Therapy
  • Clinical Development
  • Clinical Trials
  • Coping
  • Survivorship
  • Ovarian Cancer Resources
  • Contact

Tag Archives: Michael Loebinger M.D. M.A.

Researchers Are On The TRAIL To Killing Cancer With Genetically-Engineered Adult Stem Cells

Posted on May 21, 2009 by Paul Cacciatore

“Researchers in London have demonstrated the ability of adult stem cells from bone marrow (mesenchymal stem cells, or MSCs) to deliver a cancer-killing protein to tumors.  The genetically engineered stem cells are able to home to the cancer cells, both in culture and in mouse models, and deliver TNF-related apoptosis-inducing ligand (TRAIL), destroying the tumor cells while sparing normal cells. …”

Continue reading →

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • Share on Pinterest (Opens in new window) Pinterest
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Tumblr (Opens in new window) Tumblr
  • Share on Reddit (Opens in new window) Reddit
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email
Like Loading...
Posted in Medical Study Results, Meeting Highlights, Novel Therapies | Tagged adult stem cells, American Thoracic Society, Centre For Respiratory Research, Medical Research Council UK, mesenchymal stem cells, Michael Loebinger M.D. M.A., ovarian cancer, S.M. Janes M.D. Ph.D., TNF-related apoptosis-inducing ligand, TRAIL, University College of London, vector | Leave a comment
"Once you choose hope, anything is possible." -- Christopher Reeve

Categories

RSS Google Ovarian Cancer News

  • Bar Levy: Integrating the Patient Voice Across the Full Ovarian Cancer Drug Development Lifecycle - Oncodaily
  • ROSELLA Trial Data Signal New Progress in Platinum-Resistant Ovarian Cancer - Targeted Oncology
  • Dr Monk on Pivotal Biomarkers in Recurrent Ovarian Cancer - OncLive
  • Radon Exposure and Ovarian Cancer: A Preventable Risk? - Medscape
  • Bowel and Ovarian Cancer Cases Rise Among U.K. Young Adults - Inside Precision Medicine
  • Woman Learned of Ovarian Cancer Nearly 3 Decades Younger Than Average Diagnosis - People.com
  • Rethinking ovarian cancer III: the past decade and future directions - Nature
  • Rising bowel and ovarian cancer rates in younger adults raise new concerns - News-Medical
  • Oaks Survivors Parade honors cancer survivors at Churchill Downs - whas11.com
  • Radon gas increases risk of ovarian cancer, UND study says - University of North Dakota

Top Posts

  • About
    About
  • Contact
    Contact
  • Working Smarter, Not Harder: Use of Anti-Estrogen Therapy to Battle Recurrent Ovarian Cancer
    Working Smarter, Not Harder: Use of Anti-Estrogen Therapy to Battle Recurrent Ovarian Cancer
  • Colectomy "Contributes Significantly" to Ovarian Cancer Maximal Surgical Cytoreduction
    Colectomy "Contributes Significantly" to Ovarian Cancer Maximal Surgical Cytoreduction
  • ASCO 2011: Novel Multi-targeted Agent Cabozantinib (XL184) Has Significant Effect on Several Advanced Solid Tumors
    ASCO 2011: Novel Multi-targeted Agent Cabozantinib (XL184) Has Significant Effect on Several Advanced Solid Tumors
  • The Mirror: "What is the Meaning of Life?"
    The Mirror: "What is the Meaning of Life?"
  • Ovarian Cancer Survivor Seeks "Compassionate Use" Drug Exemption From BioMarin to Save Her Life
    Ovarian Cancer Survivor Seeks "Compassionate Use" Drug Exemption From BioMarin to Save Her Life
  • Gene Therapy
    Gene Therapy
  • Clinical Trials
    Clinical Trials
  • Two Studies Address Risk Reduction & Screening For BRCA 1/2 Gene Mutation Carriers
    Two Studies Address Risk Reduction & Screening For BRCA 1/2 Gene Mutation Carriers

Archives

  • May 2015
  • September 2014
  • August 2014
  • May 2014
  • March 2014
  • August 2013
  • May 2013
  • February 2013
  • January 2013
  • July 2012
  • June 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008

Blog Stats

  • 508,139 Visitors
cancer blog

Enter your email address to subscribe to Libby's H*O*P*E* & receive notifications of new posts by email.

Join 342 other subscribers

 Subscribe in a reader

Click on the orange button above if you want to (i) add Libby's H*O*P*E*(tm) updates to a web-based or other reader, or (ii) embed a Libby's H*O*P*E* (tm) update widget on your desktop, website or blog.

Donate To Ovarian Cancer Research

OCRF is the largest U.S. private funding agency supporting ovarian cancer research. It is a not-for-profit, 501(c)(3) organization. Click on the OCRF logo above to make a donation.

Strategic Partners

Podcasts

Join Us In the Fight Against Ovarian Cancer

RSS New Ovarian Cancer Clinical Trials (Past 14 Days)

  • NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors
  • Early Diagnosis of High-grade Serous Epithelial Ovarian Cancer Through the Analysis of DNA Derived From Pap Test Smear.
  • Enumeration and Functional Analysis of Circulating Tumor Cells for Homologous Recombination: a Prospective Single-center Study on Advanced/Metastatic Solid Tumors
  • 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
  • An Integrated Genomic Approach to Assess Genetic Risk and Drug Sensitivity
  • Tiaoshen Anti-cancer Protocol and CBT for Insomnia and Survival in Ovarian Cancer
  • A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
  • A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
  • A Randomized Controlled Trial Evaluating the Feasibility and Preliminary Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Advanced Epithelial Ovarian Cancer
  • A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid Tumors

RSS New Adult Solid Tumor Clinical Trials (Past 14 Days)

  • NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors
  • Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation
  • Safety and Tolerability of NCP-IL-22BP mRNA in Advanced Solid Tumors
  • Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid Tumors
  • Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
  • Safety and Preliminary Activity of BI115 in Advanced SCLC
  • A Multicenter, Randomized, Cohort, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy
  • Enumeration and Functional Analysis of Circulating Tumor Cells for Homologous Recombination: a Prospective Single-center Study on Advanced/Metastatic Solid Tumors
  • 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
  • Allogeneic WTX-212C in Advanced Solid Tumors

RSS Medical Studies

  • Different Immune Cells Modified With Chimeric Antigen Receptors Are Being Applied to Ovarian Cancer: Which Is the Most Effective?
  • YAP inactivation-mediated autophagy inhibition contributes to cisplatin resistance in ovarian cancer cells
  • A machine learning framework combining cfDNA fragmentomics and serum biomarkers for early ovarian cancer detection
  • Reduced type 2 epithelial-mesenchymal transition serves as a risk factor for the progression from endometriosis to endometriosis-associated ovarian cancer
  • Cascade catalysis-based signal amplification for colorimetric detection of β-galactosidase activity and its application
  • Multi-scale evidence chain: Linking environmental BPA exposure to ovarian cancer through integrated omics and experimental models
  • Targeting Oncogenic lncRNA KRT7-AS to Induce Ferroptosis Suppresses Ovarian Cancer Progression
  • A Novel Partial EMT-Associated Transcriptomic Signature for Prognostic Stratification in Ovarian Cancer
  • Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Meta-Analysis of All Randomized Clinical Trials with Subgroup Analysis by Patient Profile
  • Laparoscopic Versus Open Surgery for Advanced-Stage Ovarian Cancer: A 10-Year Data Analysis

Recent Comments

Prometey Bank's avatarPrometey Bank on World Ovarian Cancer Day: Toge…
mikaljhohnashly's avatarmikaljhohnashly on World Ovarian Cancer Day: Toge…
Jan C. Calthrop's avatarJan C. Calthrop on Lab-On-A-Chip: Veridex & M…
Paul Cacciatore's avatarPaul Cacciatore on About
Building a Team for… on About
Kathleen's avatarKathleen on About
Paul Cacciatore's avatarPaul Cacciatore on About
Liz's avatarLiz on About
Paul Cacciatore's avatarPaul Cacciatore on Dana Farber Webchat: The Lates…
Judith Marengere's avatarJudith Marengere on Dana Farber Webchat: The Lates…
Paul Cacciatore's avatarPaul Cacciatore on Dana Farber Webchat: The Lates…
Franca Pichini's avatarFranca Pichini on Dana Farber Webchat: The Lates…
painspeaks's avatarpainspeaks on SU2C Announces the Formation o…
marcy westerling's avatarmarcy westerling on SU2C Announces the Formation o…
anne's avataranne on Dana-Farber Oncologists Differ…

Blogroll

  • Site Meter Site Meter

Cancer Organizations

  • American Cancer Society
  • National Cancer Institute

Everyday Heroes

  • Are You There Cancer? It's Me, Jennie.
  • Bald Heads Are Sexy
  • Butterfly Ballet
  • Cancer Queen
  • Carrie's Journey
  • Chris Bledy
  • Diary of a Cancer Patient
  • I Want To Breathe
  • Janine's News
  • Journey Through Ovarian Cancer
  • Kristi & Brian: Living! With Cancer
  • Laurey Bikes
  • Life Cycle
  • livingly dying
  • Marcheline Bertrand Remembered
  • Meghan's Message
  • Monday Hearts For Madalene
  • My Journey With Teal
  • Nobody Has Ovarian Cancer
  • Out Shine Ovarian Cancer
  • OVACOM
  • Ovarian Cancer News
  • Ovarian Cancer?? pass the wine … now!
  • Scrambled Eggs, Surviving Ovarian Cancer
  • Shannon Miller Lifestyle
  • Still Smiling
  • Strong As Steele
  • Tenaciously Teal
  • The Carcinista
  • What? Me Worry?
  • Will There Be Cows In Heaven?
  • Women of Teal

Inspirational Cancer Advocates

  • Bald Is Beautiful
  • Bicycling For Ovarian Cancer (Craig Broeder)
  • Christine Druther
  • Fran Drescher
  • Imerman Angels
  • Jenn Sommermann: Training For a Cure
  • Jim Valvano
  • Laurey Masterton
  • Maddie Kullen
  • Mothers With Cancer
  • Randy Pausch
  • Sean Swarner
  • Standup2cancer
  • The Rock Band N.E.D.

Ovarian Cancer News Archive

  • Ovarian Cancer News Archive

Ovarian Cancer Organizations

  • National Breast & Ovarian Cancer Connection
  • National Ovarian Cancer Coalition
  • Ovarian Cancer National Alliance
  • Ovarian Cancer Research Fund
  • Ovations For the Cure

U.S. Treatment Centers

  • National Comprehensive Cancer Network Member Institutions
  • NCI-Designated Cancer Centers

Video Archive

  • Ovarian Cancer Video Library
Copyright 2008 - 2016 Paul Cacciatore, Libby's H*O*P*E*(TM), *Helping *Ovarian Cancer Survivors *Persevere Through *Education(TM), all rights reserved.
Paul Cacciatore

Create Your Badge
Site Meter
Blog at WordPress.com.
  • Subscribe Subscribed
    • Libby's H*O*P*E*
    • Join 217 other subscribers
    • Already have a WordPress.com account? Log in now.
    • Libby's H*O*P*E*
    • Subscribe Subscribed
    • Sign up
    • Log in
    • Report this content
    • View site in Reader
    • Manage subscriptions
    • Collapse this bar
%d